Showing papers in "Value in Health in 2000"

TL;DR: New users showed low persistence on statins in a cohort of socially assisted persons aged 45-64, in spite of the minimal financial cost of the drug for such beneficiaries of Québec's provincial health plan.

TL;DR: The results of this study suggest that patients with transformed migraine have a lower health-related quality of life than patients with migraine and highlight the importance of effective management of headaches to avoid the progression of migraine to the more disabling transformed migraine.

TL;DR: It is clear that HRQoL results are influenced by multiple patient and disease factors, particularly age, gender, and the presence and severity of disease complications and comorbid conditions, and these factors should be considered in the design and analysis of HRZoL evaluations in type 2 diabetes patients.

TL;DR: The results indicate a significant deficit experienced by people with type 2 diabetes vs. their age group peers in the general population and confirms the need for treatment policies to focus on reducing the risk of such complications and hence improve patients' HrQoL.

TL;DR: These estimates of lifetime costs and the methodology on which they are based can be used to evaluate the cost-effectiveness of such secondary prevention strategies and can serve as a benchmark against which the lifetime costs of treating other diseases can be assessed.

TL;DR: It is argued that high quality early models form the breeding ground for later solid evidence on value for money, and are consequently both worthwhile to the pharmaceutical industry and to health care decision-makers and payers.

TL;DR: In Sweden treatment with becaplermin in conjunction with GWC consumes fewer resources and generates better outcomes than treatment withGWC alone for diabetic neuropathic ulcers, and the potential savings in costs and suffering may be important.

TL;DR: National guidelines for the economic evaluation of agents and devices should consider this issue in more depth, and existing evidence rankings should be adapted to be more appropriate to pharmacoeconomic studies.

TL;DR: The health care utilization in persons with RA is frequent and includes a number of components leading to high annual direct cost, including medications, which accounts for more than half of the total cost.

TL;DR: This study is the first of its kind to estimate the overall cost of asthma to a major employer in the United States and to profile the nature of the asthma expenses.

TL;DR: A 1-year semi-Markov model was constructed to simulate the cost-effectiveness of atypical and typical antipsychotic treatments for schizophrenia and the results obtained when it was applied to the treatment of patients with schizophrenia in the Belgian health care system.

TL;DR: The objective was to calculate the 5-year direct medical costs of second-line pharmacological management of paroxysmal and persistent Afib in France and found that Afib management places high demands on medical resources mainly through its complications and comorbidity.

TL;DR: Thromboprophylaxis with enoxaparin in hospitalized acutely ill patients over 40 years of age appears to be an efficient strategy using French cost data.

TL;DR: An initial evaluation of the direct cost of treating ribavirin-induced hemolytic anemia provides an estimate of the cost and management implications of this clinically important adverse effect.

TL;DR: Several methodological challenges in the design of medical effectiveness trials are reviewed, including whether to blind the study, definition of the patient population, degree of physician discretion in treatment, and how to collect and analyze data for patients who discontinue their originally assigned medication are reviewed.

TL;DR: The article demonstrates how both NICE requirements for both incidence-based cost-effectiveness analyses and prevalence-based estimates of the aggregate NHS impact of the new drug can be met using Markov modeling techniques.

TL;DR: In analyses of small sample sizes with skewed cost data, the bootstrap method may offer an alternative to the more traditional nonparametric or log-transformation techniques.

TL;DR: Italian pharmacoeconomists are far from reaching any consensus on methods for evaluating indirect costs, and methods need to be standardized particularly with respect to the parameters used to quantify productive time lost in monetary terms.

TL;DR: Advanced breast cancer patients initiating second-line hormone therapy with letrozole 2.5 mg have better clinical outcomes than patients receiving megestrol acetate 160 mg, and this benefit comes at an acceptable cost to the Canadian health care system.

TL;DR: In this article, the authors determine age and gender-specific drug treatment prevalence rates for overactive bladder (OAB), and compare resource use and costs among MCO members receiving drug treatment for OAB.

TL;DR: A variety of alternative multivariate analyses using a publicly available RACD are undertaken to explain and reconcile the mixed SSRI cost comparison evidence, finding the effect of sample selectivity on total depression-related and total health care expenditure is neutral across SSRIs.

TL;DR: Suboptimal drug use patterns are common and costly in Medi-Cal patients with schizophrenia who initiated therapy with conventional antipsychotics, and continuous drug therapy was not associated with lower costs.

TL;DR: The findings suggest that theSF-36 may not discriminate well between healthy and nonhealthy groups and that objective measures of health status may be required in conjunction with the use of the SF-36.

TL;DR: In this paper, the authors modify previously published models to estimate the short and long-term consequences of nevirapine triple combination therapy use in five developed countries, using clinical trial data from advanced stage patients to estimate first-year costs and consequences.

TL;DR: Adherence to clinical practice guideline-based measures was more costly than deviating from those criteria, in the short-run, and expenditures should be higher for many patients who are not treated according to guidelines.

TL;DR: A patient-specific drug safety-efficacy index was developed that combined objective clinical trial information about dose-related efficacy and toxicity with subjective perspectives on efficacy-toxicity trades, suggesting that different patients will benefit from different drugs depending on the dose prescribed and each patient's subjective assessment of the efficacy/toxicity tradeoff.